Halicin
CAS No. : 40045-50-9
(Synonyms: SU3327)
| Size | Price | Stock |
|---|---|---|
| 5mg | $75 | In-stock |
| 10mg | $120 | In-stock |
| 50mg | $400 | In-stock |
| 100mg | $600 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-107597 |
| M.Wt: | 261.30 |
| Formula: | C5H3N5O2S3 |
| Purity: | >98 % |
| Solubility: | DMSO : 62.5 mg/mL (ultrasonic) |
Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. Halicin shows less active against p38α and Akt kinase[1][2]. IC50 & Target:IC50: 0.7 μM (JNK); 239 nM (JNK-JIP interactions)[1] In Vitro:Halicin (compound 9) is able to inhibit TNF-α stimulated phosphorylation of c-Jun in HeLa cells (EC50 = 6.23 μM)[1].
Halicin (25 nM) pretreatment of human-derived cerebral microvascular endothelial cells (hCMEC/D3) effectively reduces LPS-induced polymorphonuclear leukocytes (PMN) rolling/adhesion to hCMEC/D3, prevents activation of AP-1, and significantly reduces expression of VCAM-1[3]. In Vivo:Halicin (Compound 9; 25 mg/kg; intraperitoneal injection; male BKS.Cg-+Leprdb/+Leprdb/OlaHsd db/db mice) treatment possesses the ability to restore insulin sensitivity in mice models of diabetes[1].
Halicin (Compound 9) has favorable microsomal and plasma stability (T1/2 = 27 min)[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Halicin
- Cat. No.:
- HY-107597
- Quantity:
Your information is safe with us.